4//SEC Filing
MPM BIOVENTURES 2018, L.P. 4
Accession 0001209191-21-067150
CIK 0001808865other
Filed
Nov 29, 7:00 PM ET
Accepted
Nov 30, 4:57 PM ET
Size
18.5 KB
Accession
0001209191-21-067150
Insider Transaction Report
Form 4
Transactions
- Sale
Common Stock
2021-11-29$34.46/sh−10,073$347,116→ 3,019,118 total(indirect: See Footnote) - Sale
Common Stock
2021-11-26$35.49/sh−6,545$232,282→ 3,035,320 total(indirect: See Footnote) - Sale
Common Stock
2021-11-26$36.03/sh−6,129$220,828→ 3,029,191 total(indirect: See Footnote) - Sale
Common Stock
2021-11-29$35.37/sh−298$10,540→ 3,018,820 total(indirect: See Footnote)
Transactions
- Sale
Common Stock
2021-11-29$34.46/sh−10,073$347,116→ 3,019,118 total(indirect: See Footnote) - Sale
Common Stock
2021-11-26$36.03/sh−6,129$220,828→ 3,029,191 total(indirect: See Footnote) - Sale
Common Stock
2021-11-26$35.49/sh−6,545$232,282→ 3,035,320 total(indirect: See Footnote) - Sale
Common Stock
2021-11-29$35.37/sh−298$10,540→ 3,018,820 total(indirect: See Footnote)
Transactions
- Sale
Common Stock
2021-11-26$36.03/sh−6,129$220,828→ 3,029,191 total(indirect: See Footnote) - Sale
Common Stock
2021-11-29$35.37/sh−298$10,540→ 3,018,820 total(indirect: See Footnote) - Sale
Common Stock
2021-11-26$35.49/sh−6,545$232,282→ 3,035,320 total(indirect: See Footnote) - Sale
Common Stock
2021-11-29$34.46/sh−10,073$347,116→ 3,019,118 total(indirect: See Footnote)
Footnotes (13)
- [F1]Transaction effected pursuant to a plan established pursuant to Rule 10b5-1.
- [F10]The shares are held as follows: 1,711,605 by BV 2014, 97,289 by BV 2014(B), 58,912 by AM BV2014, 1,081,013 by BV 2018, 48,966 by BV 2018(B) and 21,333 by AM BV2018. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any.
- [F11]The shares were sold as follows: 178 by BV 2014, 6 by AM BV2014, 112 by BV 2018 and 2 by AM BV2018.
- [F12]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.125 to $35.67 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F13]The shares are held as follows: 1,711,427 by BV 2014, 97,289 by BV 2014(B), 58,906 by AM BV2014, 1,080,901 by BV 2018, 48,966 by BV 2018(B) and 21,331 by AM BV2018. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any.
- [F2]The shares were sold as follows: 3,899 by MPM BioVentures 2014, L.P. ("BV 2014"), 134 by MPM Asset Management Investors BV2014 LLC ("AM BV2014"), 2,463 by MPM BioVentures 2018, L.P. ("BV 2018") and 49 by MPM Asset Management Investors BV2018 LLC ("AM BV2018"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV 2014 LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV 2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC ("BV 2018 LLC") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Messrs. Evnin and Foley are managing directors of BV 2014 LLC and BV 2018 LLC.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.915 to $35.91 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]The shares are held as follows: 1,721,258 by BV 2014, 97,289 by, 59,245 by AM BV2014, 1,087,109 by BV 2018, 48,966 by BV 2018(B) and 21,453 by AM BV2018. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any.
- [F5]The shares were sold as follows: 3,652 by BV 2014, 126 by AM BV2014, 2,306 by BV 2018 and 45 by AM BV2018.
- [F6]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.92 to $36.39 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F7]The shares are held as follows: 1,717,606 by BV 2014, 97,289 by BV 2014(B), 59,119 by AM BV2014, 1,084,803 by BV 2018, 48,966 by BV 2018(B) and 21,408 by AM BV2018. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any.
- [F8]The shares were sold as follows: 6,001 by BV 2014, 207 by AM BV2014, 3,790 by BV 2018 and 75 by AM BV2018.
- [F9]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.06 to $34.86 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Documents
Issuer
iTeos Therapeutics, Inc.
CIK 0001808865
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001729505
Filing Metadata
- Form type
- 4
- Filed
- Nov 29, 7:00 PM ET
- Accepted
- Nov 30, 4:57 PM ET
- Size
- 18.5 KB